問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Hematology & Oncology

Division of Thoracic Medicine

Division of General Internal Medicine

Division of Infectious Disease

更新時間：2023-09-19

連銘渝Lien, Ming-Yu
  • Principal Investigator
  • Clinical Trial Experience (year) 13 years

Recruiting Trial

144Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

連銘渝

List

249Cases

2020-08-14 - 2027-07-24

Phase III

A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

  • Condition/Disease

    Locally Advanced Squamous Cell Carcinoma of the Head and Neck

  • Test Drug

    DEBIO 1143

Participate Sites
10Sites

Recruiting8Sites

Terminated2Sites

2019-09-01 - 2022-12-31

Phase II

A Multicenter, Open Label Single-Arm, Phase 2 Study of Zandelisib (ME-401) in Subjects With Follicular Lymphoma and Marginal Zone Lymphoma After Failure of Two or More Prior Systemic Therapies (The TIDAL Study)

  • Condition/Disease

    Follicular Lymphoma and Marginal Zone Lymphoma After Failure of Two or More Prior Systemic Therapies

  • Test Drug

    ME-401

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

2016-01-06 - 2019-06-30

Phase II

A RANDOMIZED, MULTICENTER, DOUBLE-BLIND PHASE 2 STUDY OF PALBOCICLIB PLUS CETUXIMAB VERSUS CETUXIMAB FOR THE TREATMENT OF HUMAN PAPILLOMAVIRUS-NEGATIVE, CETUXIMAB-NAÏVE PATIENTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AFTER FAILURE OF ONE PRIOR PLATINUM-CONTAINING CHEMOTHERAPY REGIMEN

  • Condition/Disease

    RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK

  • Test Drug

    PD-0332991

Participate Sites
6Sites

Terminated6Sites

2016-12-26 - 2021-04-08

Phase III

A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY (CISPLATIN PLUS DEFINITIVE RADIATION THERAPY) VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN THE FRONT-LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK

  • Condition/Disease

    Squamous Cell Carcinoma of the Head and Neck

  • Test Drug

    MSB0010718C 20mg/ml Solution for Infusion

Participate Sites
8Sites

Terminated7Sites

張牧新
Taipei Veterans General Hospital

2017-01-01 - 2021-11-17

Phase III

A phase III randomized open-label multi-center study of ruxolitinib versus best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation

  • Condition/Disease

    Corticosteroid Refractory Acute Graft vs Host Disease

  • Test Drug

    INC424

Participate Sites
3Sites

Terminated2Sites

2015-06-01 - 2017-09-30

Phase II

A multi-center, randomized, double-blind, placebo controlled, study to evaluate the efficacy and safety of CSJ148 compared to placebo to prevent human cytomegalovirus (HCMV) replication in stem cell transplant patients

  • Condition/Disease

    prevent human cytomegalovirus (HCMV) replication in stem cell transplant patients

  • Test Drug

    CSJ148

Participate Sites
4Sites

Terminated3Sites

2015-04-01 - 2022-04-22

Phase III

A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LD-DEX) versus Bortezomib and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma (MM)

  • Condition/Disease

    Relapsed or Refractory Multiple Myeloma (MM)

  • Test Drug

    Pomalidomide

Participate Sites
8Sites

Terminated7Sites

2017-02-10 - 2020-01-30

Phase III

A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Subjects With New Onset Chronic Graft Versus Host Disease (cGVHD)

  • Condition/Disease

    Chronic Graft Versus Host Disease (cGVHD)

  • Test Drug

    Imbruvica®

Participate Sites
3Sites

Terminated2Sites

2022-06-01 - 2022-12-27

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2020-09-01 - 2023-09-20

Phase I

A Phase 1b Study of ASP1951, a GITR Agonistic Antibody, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    ASP1951

Participate Sites
3Sites

Recruiting3Sites

邱昌芳
China Medical University Hospital

Division of Hematology & Oncology

1 21 22 23 24 25
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB